Pediatric Oncology: Lymphoblastic Leukemia Trials: AALL2131
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Gastrointestinal Cancer Trials: DS7300-202
A phase 3, multicenter, randomized, open-label study of Ifinatamab Deruxtecan (I-DXd) in subjects with pretreated advanced or metastatic esophageal squamous cell carcinoma (ESCC; IDeate-Esophageal01)
Gynecologic Oncology Trials: C5721005
A prospective low-interventional phase 4 single-arm study of ocular assessments in patients treated with Tivdak in recurrent or metastatic cervical cancer
Lung Cancer Trials: M18-868
A Phase 3 open-label, randomized, controlled, global study of Telisotuzumab Vedotin (ABBV-399) versus Docetaxel in subjects with previously treated c-Met+, EGFR wildtype, locally advanced/metastatic non-squamous non-small cell lung cancer
Lung Cancer Trials: SUNRAY 01
A global pivotal study in participants with KRASG12C mutant locally advanced or metastatic NSCLC comparing first-line treatment of LY3537982 and Pembrolizumab vs. placebo and Pembrolizumab in those with PDL1 expression ≥ 50% and LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs. placebo and Pembrolizumab, Pemetrexed, and Platinum regardless of PD-L1 expression
Breast Cancer Trials: Playback Health
Using Playback Health to improve patient recall and overall satisfaction following breast surgery consultations
Lung Cancer Trials: A081801 – ACCIO
Integration of Immunotherapy into Adjuvant Therapy for resected NSCLC.
Bladder Cancer Trials: A032103: MODERN:
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Breast Cancer Trials: CONCURxP : EAQ221CD
Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)
Breast Cancer Trials: A012103: OptimICE-PCR:
De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy